HUMA NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Humacyte Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 0.62 USD
-6.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -32.7% below the Trend Line and sits at 3.5% of its 52-week range. The latest completed week returned -6.0%, after a -11.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is mixed with 29/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 18 out of 100
Latest Close 0.62 USD 24 Jul 2026
1W Return -6.0% latest completed week
4W Return -11.8% short-term follow-through
12W Return -26.9% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -6.0% Latest completed week; four-week move -11.8%. Indicator stack 0/43 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 29/100 conviction; expected move 21.3%. News sentiment 51/100 58 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -32.7% below the Trend Line and sits at 3.5% of its 52-week range. The latest completed week returned -6.0%, after a -11.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1812-week average 0.14

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.18Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -11.8% over four weeks, -26.9% over 12 weeks, and -75.3% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-6.0%
4W-11.8%
12W-26.9%
26W-40.5%
52W-75.3%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.04Latest activity-pressure read.
Pressure change-96.1%Four-week change in activity pressure.
Leadership-53.30Latest relative-leadership reading.
RS change2.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength1/100Blend of value, momentum, and quality. Underlying universe rank 100; rank 1 is best.
Value11/100Relative valuation strength. Underlying universe rank 90; rank 1 is best.
Quality1/100Profitability and accounting quality. Underlying universe rank 100; rank 1 is best.
Momentum2/100Medium-term price momentum. Underlying universe rank 99; rank 1 is best.
Growth11/100Revenue and earnings growth. Underlying universe rank 90; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
83.6x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-54.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-748.5%
Gross profit retained from each unit of revenue.
Operating margin
-4318.9%
Operating profit retained from revenue.
Free-cash-flow margin
-4995.7%
Free cash flow generated from revenue.
Return on invested capital
-225.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-74.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
-44.6%
Net share repurchases relative to market value.
Shareholder yield
-44.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

HUMA shows mixed options pressure with a 29/100 conviction score, put-call volume ratio of 0.89, expected move of 21.3%, and Sharemaestro trend signal inactive.

Conviction29/100
Expected move21.3%
Put/call volume0.89
Pressure17
Speculation11
Volatility96
Trend agreement37
Open options detail
Insider activity13 / 2

13 acquisitions and 2 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 58 relevant articles.

13 positive · 35 neutral · 10 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move21.3%Nearest-chain priced movement where available.
52-week drawdown-77.3%Distance below the 52-week high.
13-week volatility15.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+23.9%Week of 8 May.
Worst week-32.5%Week of 20 Mar.
Latest week-6.0%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains3
Flat weeks0
Modest losses4
Sharp losses11
Recent vol15.7%13-week weekly-return volatility.
Base vol13.3%52-week weekly-return volatility.
Up/down split19/33Count of positive and negative weeks in the 52-week window.
Average skew12.0% / -9.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis33/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.18; No reversal markers Factors3/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 96; Small Cap Core rank 93 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options40/100

HUMA shows mixed options pressure with a 29/100 conviction score, put-call volume ratio of 0.89, expected move of 21.3%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 21.3% Sentiment51/100

Weighted news tone is neutral across 58 relevant articles.

Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution Insiders13 / 2

13 acquisitions and 2 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.62 USD-6.0%0.93 USD3.03 USD0.04-53.3027.2MOff
17 Jul 20260.66 USD-4.2%0.94 USD3.05 USD0.39-52.7731.8MOff
10 Jul 20260.69 USD-2.3%0.96 USD3.06 USD0.59-54.1647.5MOff
3 Jul 20260.71 USD0.2%0.98 USD3.08 USD0.85-53.6182.0MOff
26 Jun 20260.71 USD-23.3%1.00 USD3.09 USD1.04-54.58171.7MOff
19 Jun 20260.92 USD-12.4%1.02 USD3.11 USD1.15-44.7937.9MOff
12 Jun 20261.05 USD-21.9%1.03 USD3.12 USD1.28-37.0055.1MOff
5 Jun 20261.35 USD3.8%1.03 USD3.13 USD1.30-19.5538.6MOff
29 May 20261.30 USD23.8%1.03 USD3.15 USD1.24-27.7733.7MOff
22 May 20261.05 USD12.9%1.04 USD3.17 USD0.97-41.5425.6MOff
15 May 20260.93 USD-12.3%1.07 USD3.18 USD0.52-48.9756.4MOff
8 May 20261.06 USD23.9%1.09 USD3.20 USD0.04-43.3029.5MOff
1 May 20260.86 USD22.2%1.11 USD3.22 USD-0.37-52.0721.8MOff
24 Apr 20260.70 USD-1.4%1.15 USD3.25 USD-0.53-60.5719.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.